Cell Reports, Volume 17

Supplemental Information

eFORGE: A Tool for Identifying

Cell Type-Specific Signal in Epigenomic Data

Charles E. Breeze, Dirk S. Paul, Jenny van Dongen, Lee M. Butcher, John C. Ambrose, James E. Barrett, Robert Lowe, Vardhman K. Rakyan, Valentina Iotchkova, Mattia Frontini, Kate Downes, Willem H. Ouwehand, Jonathan Laperle, Pierre-Étienne Jacques, Guillaume Bourque, Anke K. Bergmann, Reiner Siebert, Edo Vellenga, Sadia Saeed, Filomena Matarese, Joost H.A. Martens, Hendrik G. Stunnenberg, Andrew E. Teschendorff, Javier Herrero, Ewan Birney, Ian Dunham, and Stephan Beck



| | -10010 binomial p-value | 0 10 000000000000000000000000000000000 |
|--|---------------------------------|--|
| | FE | |
| IFL q−value q < 0.01 | DR q-value | |
| • | • | 0 0 |
| • | • |) 0 (|
| Blood | Blood | |
| 0 | 0 0 0 | • |
| 0 0 | 0 0 | 0 0 |
| Breast | Breast | • |
| • | 0 8 1 1 | 8 |
| ES Ce E | Cell Cell | 0 0 |
| 0 | | . 0 |
| • Fetal Adrenal Fetal Brain | - o Fetal Adrenal | |
| mmo Fetal Heart | Fetal Heart | - - - |
| Fetal Intestine, Large | Fetal Intestine, Large | Fetal Intestin |
| | | |
| Fetal Kidney | Fetal Kidney | - o Feta |
| Fetal Lung | Fetal Lung | |
| • | 8 8 | • |
| • Fetal Muscle | etal Muscle | • • |
| 8 | | |
| D 0 | 5 0 | • |
| Eetal Placenta | - oo Fetal Placenta | Fetal F |
| Fetal Renal Cortex | Fetal Renal Cortex | Fetal Rena |
| Fetal Renal Pelvis | oco co Fetal Renal Pelvis | Fetal Ren |
| etal Skin | • Fetal Skin | Ŭ, ° |
| Petal Spinal Cord | Fetal Spinal Cord | - • Fetal Spi |
| Fetal Stomach | Eetal Stomach | Fetal S |
| • Fetal Testes | - o Fetal Testes | Feta |
| • | | |
| 8. | 8 8 | • |
| Fibroblast | Fibroblast | :: |
| 8 8 8 | 8 • • | ::1 |
| IPS cell | | 0 0 0 0 |
| Fung Bunz | Fund | 8 |
| Skin | Skin | 8 8 |
| | | |

Figure S1. eFORGE analysis of mixed DHS overlapping tDMP and cDMP sets. Related to Figure 2. [A]: eFORGE analysis of a mixed set of DHS-overlapping tDMPs. The top panel shows enrichment in lung for a list of 55 DHS-overlapping lung tDMPs. The middle panel shows enrichment in kidney for a set of 51 DHS-overlapping kidney tDMPs. The bottom panel shows mixed tissue-specific enrichment for lung and kidney for the merged list of 106 probes. [B]: eFORGE analysis of a mixed set of DHS-overlapping cDMPs. The top panel shows enrichment results from testing 148 monocyte specific DMPs, highlighting the CD14+ category. The middle panel shows enrichment results for 148 B cell specific DMPs, highlighting mainly the CD19+ and spleen categories. The bottom panel shows enrichment results for a mixed set of both cell type-specific probe sets. As evident from the mixed set, enrichments for both cell types are still present.

| Intergenic region | Island | Shore_Shelf | NA |
|--------------------------|--------|-------------|----|
| Within the 200 bp prior | Island | Shore_Shelf | NA |
| to a Transcription start | | | |
| site | | | |
| 1st Exon | Island | Shore_Shelf | NA |
| Within the 1500 bp | Island | Shore_Shelf | NA |
| prior to a Transcription | | | |
| start site | | | |
| 3' Untranslated region | Island | Shore_Shelf | NA |
| 5' Untranslated region | Island | Shore_Shelf | NA |
| Gene Body | Island | Shore_Shelf | NA |

Table S1. Data categories for background probe matching in eFORGE. Related to Figure 1. Column 1 indicates gene-centric category and columns 2, 3 and 4 indicate the three subsequent CpG Island-centric subcategories that separate probes from each gene-centric category.

| IGR | Shore | 21121 |
|---------|--------|--------|
| IGR | Island | 22392 |
| IGR | NA | 57749 |
| IGR | Shelf | 18390 |
| TSS200 | Shore | 9372 |
| TSS200 | Island | 32996 |
| TSS200 | Shelf | 857 |
| TSS200 | NA | 9058 |
| 1stExon | Shore | 2506 |
| 1stExon | Island | 15581 |
| 1stExon | Shelf | 368 |
| 1stExon | NA | 4282 |
| TSS1500 | Shore | 31022 |
| TSS1500 | Island | 21610 |
| TSS1500 | Shelf | 1685 |
| TSS1500 | NA | 14667 |
| 3'UTR | Shore | 3426 |
| 3'UTR | Island | 1992 |
| 3'UTR | Shelf | 1802 |
| 3'UTR | NA | 10274 |
| 5'UTR | Shore | 9460 |
| 5'UTR | Island | 17581 |
| 5'UTR | NA | 11855 |
| 5'UTR | Shelf | 3789 |
| Body | Shore | 35160 |
| Body | Island | 38102 |
| Body | Shelf | 20253 |
| Body | NA | 68162 |
| | Total | 485512 |

Table S2. Numbers of probes in each background bin category in eFORGE. Related to Figure 1. The selection of each background probe matching each DMP in the test set is based on gene-centric and CpG island-centric annotation.

| SetSize | Ν | p<0.05 | p<0.01 | q<0.05 | q<0.01 | F | p1f | p2f | qlf | q2f |
|---------|--------|--------|--------|--------|--------|------|------|-----|-----|-----|
| 5 | 625000 | 2418 | 190 | 0 | 0 | 5000 | 936 | 104 | 0 | 0 |
| 10 | 625000 | 23686 | 3602 | 23 | 0 | 5000 | 2829 | 943 | 11 | 0 |
| 15 | 625000 | 5721 | 597 | 0 | 0 | 5000 | 1338 | 283 | 0 | 0 |
| 20 | 625000 | 9313 | 1226 | 32 | 0 | 5000 | 1887 | 426 | 3 | 0 |
| 30 | 625000 | 13487 | 1591 | 4 | 0 | 5000 | 2274 | 542 | 1 | 0 |
| 40 | 625000 | 10877 | 1356 | 6 | 0 | 5000 | 1999 | 475 | 5 | 0 |
| 50 | 625000 | 13714 | 1554 | 16 | 0 | 5000 | 2222 | 570 | 4 | 0 |
| 100 | 625000 | 12973 | 1593 | 1 | 0 | 5000 | 2229 | 554 | 1 | 0 |

Table S3. Results from testing 5000 random probe sets for false positives on ENCODE data. Related to Figure 1. At q<0.01 we do not observe any false positives for any input test size (ranging between 5 and 100 probes).

| SetSize | Ν | p<0.05 | p<0.01 | q<0.05 | q<0.01 | F | p1f | p2f | qlf | q2f |
|---------|---------|--------|--------|--------|--------|------|------|------|-----|-----|
| 5 | 1495000 | 4161 | 313 | 0 | 0 | 5000 | 1013 | 142 | 0 | 0 |
| 10 | 1495000 | 54869 | 7930 | 264 | 0 | 5000 | 2998 | 1065 | 6 | 0 |
| 15 | 1495000 | 10519 | 904 | 0 | 0 | 5000 | 1544 | 316 | 0 | 0 |
| 20 | 1495000 | 16263 | 1570 | 1 | 0 | 5000 | 1894 | 431 | 1 | 0 |
| 30 | 1495000 | 28526 | 3279 | 0 | 0 | 5000 | 2214 | 602 | 0 | 0 |
| 40 | 1495000 | 22855 | 2557 | 129 | 0 | 5000 | 1997 | 496 | 2 | 0 |
| 50 | 1495000 | 30460 | 3430 | 1 | 0 | 5000 | 2341 | 672 | 1 | 0 |
| 100 | 1495000 | 23173 | 2480 | 1 | 0 | 5000 | 2051 | 510 | 1 | 0 |

Table S4. Results from testing 5000 random probe sets for false positives on Roadmap Epigenomics data. Related to Figure 1. At q<0.01 we do not observe any false positives for any input test size (ranging between 5 and 100 probes).

| Datatype | Assay | Celltype | Consortium |
|-----------------|----------|------------|------------|
| All (1785) | 0.49 {6} | 0.08 {305} | -0.04 {3} |
| H3K36me3 (255) | 1 {1} | 0.32 {138} | -0.04 {2} |
| H3K4me3 (292) | 1 {1} | 0.25 {165} | -0.01 {2} |
| H3K4me1 (239) | 1 {1} | 0.37 {128} | 0.06 {2} |
| H3K27me3 (253) | 1 {1} | 0.35 {134} | 0.03 {2} |
| H3K9me3 (238) | 1 {1} | 0.26 {126} | 0.07 {2} |
| DNase-Seq (508) | 1 {1} | 0.40 {183} | 0.01 {3} |

Table S5: Adjusted Rand Index (ARI) results for ENCODE, BLUEPRINT and Roadmap Epigenomics data clustering with GeEC. Related to Figure 1. An ARI score around zero means that the labels of a category are randomly distributed among clusters, while a positive value (max of 1) means that the labels of a category are enriched in a defined cluster. Numbers in () represent the number of datasets in each group of datasets, while numbers in { } represent the number of different labels for each category and group. ARI results show that the contribution of "Consortium" is small, and the main labels for clustering are "Assay" and "Celltype".

Table S6: eFORGE BLUEPRINT sample data. Related to Figure 1. Sample data includes file name, lab of origin, type of data (all samples are DHS), cell name, tissue of origin, short cell name (for plotting), sample individual data (sex, age and disease status), sample URL and URL of original file. Samples include both primary cells and transformed cell lines. This table has been supplied as a Supplemental Excel file.

| Study | Number of | | | | | | |
|--------|-----------|----------|--------------------|-------------|------------------------|----------------------------|----------------------------------|
| number | samples | PMID | Disease/Trait | Platform | Analysed tissue | eFORGE tissue | eFORGE link |
| | | | | | | | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | | E.v1.2/files/0xC8FF623812ED11 |
| | | | | | | Stem cell signal for 1000 | E6B81D459BF8274B10/addition |
| | | | Ageing in blood | | Whole blood, | probes from additional | al_file_4_ageing_EWAS.450k.erc |
| 1 | 2442 | 23034122 | and brain **;*** | 27 and 450k | leukocytes, brain | file 4 | 2-DHS.chart.pdf |
| | | | | | | Stem cell signal for | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | probes from | E.v1.2/files/0x4D980C8425B311 |
| | | | Adrenocortical | | Adrenocortical | supplemental table 1 | E6B2D23DDCF8274B10/index.h |
| 2 | 135 | 23093492 | carcinoma** | 27k | carcinoma tumours | (362 probes) under 0.01 | tml |
| | | | | | | Mixed enrichment for | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | several tissues for probes | E.v1.2/files/0x439DAF16242011 |
| | | | | | | from Supplemental Table | E6B310C6D3F8274B10/No_labe |
| 3 | 910 | 23578854 | Breast cancer | 27k | blood | 1 | l_given.450k.erc2-DHS.chart.pdf |
| | | | | | 29 normal renal cortex | Stem cell enrichment and | |
| | | | | | tissue, 109 tumor | other mixed enrichment | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | Clear cell renal | | tissues and 107 | for probes from | E.v1.2/files/0x5550140A115211E |
| | | | cell carcinomas | | matched adjacent | supplemental table 2 | 6AF74B300F9274B10/No_label_ |
| 4 | 138 | 22610075 | (RCCs)** | 27k | normal tissue | (801 probes) | given.450k.erc2-DHS.chart.pdf |
| | | | | | | | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | Mixed enrichment for | E.v1.2/files/0xF3288FF2240A11 |
| | | | Congenital Heart | | | probes from Table S1 | E6A6E27FB6F8274B10/No_labe |
| 5 | 367 | 21297937 | Defects (CHDs) | 27k | blood | (top 20 positive probes) | l_given.450k.erc2-DHS.chart.pdf |
| | | | | | | | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | Mixed enrichment for | E.v1.2/files/0x149CA7F4120E11 |
| | | | | | | probes from | E68EF480F5F8274B10/bell_diab |
| | | | Diabetic | | | supplemental table s1, | etic_nefropathy_qvals_0_15.450k |
| 6 | 192 | 20687937 | nephropathy** | 27k | Whole blood | with q values below 0.15 | .erc2-DHS.chart.pdf |
| | | | | | purified peripheral | | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | Nonhematopoietic | | blood leukocyte | CD14 cell signal for | E.v1.2/files/0x62FCC88C240D11 |
| | | | cancers and blood | | subtypes from healthy | probes from | E6A13229BAF8274B10/No_labe |
| 7 | 1230 | 22714737 | leukocyte profiles | 27k | donors | Supplemental Table 4 | l_given.450k.erc2-DHS.chart.pdf |
| | | | | | | Blood signal for probes | http://eforge.cs.ucl.ac.uk/eFORG |
| 8 | 168 | 21453505 | Parental age** | 27k | cord blood | from table s5. | E.v1.2/files/0x451A5388160D11 |

| | | | | | | | E6945594A5F8274B10/No label |
|----|-----|----------|--------------------|-----------|---------------------|---------------------------|----------------------------------|
| | | | | | | | _given.450k.erc2-DHS.chart.pdf |
| | | | | | | | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | | E.v1.2/files/0xBC47687C161411 |
| | | | Racial differences | | | Blood signal for "yes" | E6BF88B9AFF8274B10/No labe |
| 9 | 201 | 21308978 | at birth** | 27k | cord blood | probes from table s4: | 1 given.450k.erc2-DHS.chart.pdf |
| | | | | | | | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | Blood and thymus signal | E.v1.2/files/0xC4946164242011E |
| | | | | | | for probes from Bre100 | 68EC468D4F8274B10/No_label_ |
| 10 | 255 | 23579546 | Breast cancer | 27k, 450k | breast | Supplemental Table 2A | given.450k.erc2-DHS.chart.pdf |
| | | | | | | | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | Clear cell renal | | kidney (Tumour and | Kidney signal for top | E.v1.2/files/0xE35B9F46241F11 |
| | | | cell carcinoma | | adjacent non-tumour | 200 methylated 450k | E693220FD2F8274B10/No_label |
| 11 | 317 | 23526956 | (ccRCC) | 27k, 450k | tissue) | probes from table S6 | _given.450k.erc2-DHS.chart.pdf |
| | | | | | | Stem cell signal for | |
| | | | | | | probes from table s5 | |
| | | | | | | model kidney, the largest | |
| | | | | | | TCGA category (183 | |
| | | | | | | Kidney samples, | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | compared to 83 breast, | E.v1.2/files/0x2B74E1A8137B11 |
| | | | | | | 60 lung, and 42 skin | E6AF31C3D2F8274B10/No_labe |
| 12 | 656 | 23177740 | Ageing*** | 450k | Whole blood | samples): | l_given.450k.erc2-DHS.chart.pdf |
| | | | | | | Mixed enrichment with | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | blood skew for top 1000 | E.v1.2/files/0x6B81FA2E12EA11 |
| | | | | | | probes by p-value from | E6A1B50A97F8274B10/appendi |
| | | | Child | | | annex B, supplemental | x_B_child_abuse_EWAS.450k.er |
| 13 | 192 | 23332324 | maltreatment*** | 450k | Salivary DNA | information | c2-DHS.chart.pdf |
| | | | | | | Blood enrichment, with | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | other tissues, for probes | E.v1.2/files/0xA38CF988241E11 |
| | | | Rheumatoid | | | from Supplemental Table | E68AF555D0F8274B10/No_label |
| 14 | 691 | 23334450 | arthritis | 450k | blood | 3 | _given.450k.erc2-DHS.chart.pdf |
| | | | | | | | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | Smoking status | | | Stomach enrichment for | E.v1.2/files/0x0E0FEA7E240E11 |
| | | | and cancer (breast | | | breast cancer comparison | E6A42C34BBF8274B10/No_labe |
| 15 | 184 | 23175441 | and colon cancer) | 450k | blood | data | l_given.450k.erc2-DHS.chart.pdf |

| | | | | | | | http://eforge.cs.ucl.ac.uk/eFORG |
|----|------|----------|------------------|------|-------------------------|---------------------------|----------------------------------|
| | | | | | | | E.v1.2/files/0x3C0CE156121211 |
| | | | | | | Blood and thymus as | E68B61CBFAF8274B10/table_s1 |
| | | | Tobacco | | | main categories for | _tobacco.450k.erc2- |
| 16 | 1793 | 23691101 | smoking*** | 450k | Whole blood | probes from table s1 | DHS.chart.pdf |
| | | | | | | Breast epithelial | |
| | | | | | 119 lymphoblast DNA | signature potentially | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | and 19 lung | signalling macrophage | E.v1.2/files/0x81C7A70412D911 |
| | | | Tobacco | | alveolarmacrophage | (BP confirmation) for | E687D76CFFF8274B10/No_label |
| 17 | 138 | 22232023 | smoking*** | 450k | DNA | probes from table 5 | _given.450k.erc2-DHS.chart.pdf |
| | | | | | | Mixed enrichment for | |
| | | | | | | top 1000 Met M-CLL / | |
| | | | | | | unmet U-CLL probes | |
| | | | | | | from supp table 5, with 3 | |
| | | | Two subtypes of | | | out of 4 highest | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | CLL; mutated or | | | categories as blood | E.v1.2/files/0xDA59362C0E2311 |
| | | | unmutated | | Tumor samples and B | subtypes, and also lung | E6A0BCC9DDF8274B10/index.h |
| 18 | 153 | 23064414 | IGHV*** | 450k | cells from the controls | as enriched category | tml |
| | | | | | | CD14+ blood signal for a | |
| | | | | | | blood based EWAS for | |
| | | | | | | top 419 probes from | |
| | | | | | | supplemental table 2, | |
| | | | | | | agrees with article GSEA | |
| | | | | | | analysis results of | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | immune specific genes, | E.v1.1/files/0x33752BF89CD311 |
| 19 | 261 | 20019873 | Ovarian cancer** | 27k | peripheral blood | this is for 27k analysis | E4BEA3AC33AA596114 |
| | | | | | | Cross-tissue mixed | |
| | | | | | | enrichment for first 1000 | |
| | | | | | | probes from | http://eforge.cs.ucl.ac.uk/eFORG |
| | | | | | | supplemental table 2, | E.v1.2/files/0xA8797ECC0E0111 |
| | | | Thyroid cancer | | 114 snap-frozen | highest category stem | E694B84EB2F8274B10/No_label |
| 20 | 114 | 23666970 | subtypes** | 27k | thyroid samples | cell | _given.450k.erc2-DHS.chart.pdf |

Table S7. List of analysed EWAS. Related to Figure 3 and Figure 4. Study information (columns 1-6), eFORGE enriched cell type (column 7) and eFORGE URL (column 8).

Supplemental files:

File S1. eFORGE datasets. Related to Figure 1.

File S2. tDMP datasets. Related to Figure 2.

File S3. Blood tDMPs. Related to Figure 2.

File S4. Kidney tDMPs. Related to Figure 2.

File S5. Lung tDMPs. Related to Figure 2.

Supplemental Experimental Procedures

DNase I Data

Hotspots from the ENCODE project (Thurman et al., 2012) were taken from ftp://ftp.ebi.ac.uk/pub/databases/ensembl/encode/integration data jan2011/b

yDataType/openchrom/jan2011/combined_hotspots/. Hotspots from the BLUEPRINT project were downloaded from https://blueprint.genomatix.de/grid/experiments/browse (Table S6). DNase I sequencing tag alignments from the Roadmap Epigenome Project were taken from http://www.genboree.org/EdaccData/Current-Release/experiment-sample/Chromatin Accessibility/. The files that were used belong to the section of Gene Expression Omnibus (GEO) accession number GSE18927 available according to the data use embargo agreement. The Hotspot method (http://www.uwencode.org/proj/hotspot/) (John et al., 2011) (Sabo et al., 2004) was used to process the alignments, using the default parameters to give hotspot and peak files. Consolidated Roadmap Epigenomics DNase I hotspots and BroadPeak Histone mark data were retrieved from http://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/broadPeak/. Each of the datasets was assigned to the relevant cells and tissues using either consortium data or custom perl scripts from the decodings which are available from the ENCODE Data Coordination Centre tables (https://genome.ucsc.edu/encode/cellTypes.html) or from the BioSamples database sample group SAMEG31306 (http://www.ebi.ac.uk/biosamples/).

eFORGE probe weighting

Weights can be included in standalone eFORGE as follows. The initial weight can be set with the – weights flag and the step to generate subsequent weights can be set with the –step flag (see documentation at <u>https://github.com/charlesbreeze/eFORGE/blob/eforge.v1.0/eforge.pl</u>). Initial results show that weighting can improve certain enrichments, and better reflect the different significance (or effect size) of probes in the input list. However, we advise that the effect on the underlying statistics should be taken into consideration when introducing weights, and we advise caution when interpreting weighted results.

Supplemental References

John, S., Sabo, P.J., Thurman, R.E., Sung, M.-H., Biddie, S.C., Johnson, T.A., Hager, G.L., and Stamatoyannopoulos, J.A. (2011). Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. *43*, 264–268.

Sabo, P.J., Hawrylycz, M., Wallace, J.C., Humbert, R., Yu, M., Shafer, A., Kawamoto, J., Hall, R., Mack, J., Dorschner, M.O., et al. (2004). Discovery of functional noncoding elements by digital analysis of chromatin structure. Proc. Natl. Acad. Sci. U. S. A. *101*, 16837–16842.

Thurman, R.E., Rynes, E., Humbert, R., Vierstra, J., Maurano, M.T., Haugen, E., Sheffield, N.C., Stergachis, A.B., Wang, H., Vernot, B., et al. (2012). The accessible chromatin landscape of the human genome. Nature 489, 75–82.